Article

Trials begin on drop to heal ocular wounds

Bethesda, MD?The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery.

Bethesda, MD-The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery.

The randomized, double-blind, placebo-controlled study will test several dosages of TB4 in 48 diabetic patients at ophthalmic surgical centers and hospitals throughout the United States, according to the company. The sterile eye drop will be administered four times per day for up to 14 days.

The drug, which has anti-inflammatory properties and prevents cell death, has helped accelerate ophthalmic wound healing in laboratory animals.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.